Key points are not available for this paper at this time.
Introduction 8%, and basal insulin use received a Dexcom G6 following discharge. This analysis includes 14-day CGM reports at 4 weeks after discharge for the first 100 participants. Key outcomes were stratified by either RM vs MM of CGM data and include % time in range (70-180 mg/dl, TIR). Results: Among the 100 participants, 52 were RM and 48 were MM. Barriers in the MM group included incompatible cell phone (48%), no smartphone (46%), or other (4.2%). The RM group was younger, more likely to be employed, and had higher numeracy compared to the MM group. CGM data were available at 4 weeks in 62% of RM vs 56% of MM, p=0.69, and time in use was 95% in both groups. Median glucose was 176 (IQR 143, 215) vs 203 (IQR 183, 248, p=0.02) mg/dL in the RM vs MM group. Median TIR was 53% (IQR 33, 82) vs 40% (IQR 20, 49, p=0.04) in the RM vs. MM group and % time 70 mg/dl was 1% for both groups. Conclusion: Early findings suggest that CGM with RM is associated with higher TIR compared to CGM with manual downloads following hospitalization. Overcoming technological barriers to RM may improve glycemic outcomes post-discharge. Disclosure S. Folk: None. T. Sobol: None. T. Gatti: None. C. Harris: None. E.R. Faulds: Advisory Panel; Dexcom, Inc. Research Support; Dexcom, Inc., Insulet Corporation. Other Relationship; A1Control. E. Buschur: Research Support; Dexcom, Inc. K. Wyne: None. P. Duncan: None. K.M. Dungan: Advisory Panel; Eli Lilly and Company, Dexcom, Inc. Research Support; Dexcom, Inc. Advisory Panel; Elsevier. Research Support; Abbott, ViaCyte, Inc., Sanofi, Omnipod. Advisory Panel; Omnipod. Other Relationship; Up-To-Date. Speaker's Bureau; Med Learning Group, Medscape, Cardiometabolic Health Congress. Consultant; Oppenheimer Integritas. Funding Dexcom
Folk et al. (Fri,) studied this question.